The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.

Autor: Suryawanshi RK; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA., Jaishankar P; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA., Correy GJ; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA., Rachman MM; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA., O'Leary PC; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Taha TY; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA., Zapatero-Belinchón FJ; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA., McCavittMalvido M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA., Doruk YU; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Stevens MGV; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Diolaiti ME; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Jogalekar MP; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Richards AL; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA.; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, CA., Montano M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA., Rosecrans J; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA., Matthay M; Department of Medicine, University of California San Francisco, San Francisco, CA., Togo T; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA., Gonciarz RL; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA., Gopalkrishnan S; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA., Neitz RJ; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.; Small Molecule Discovery Center, University of California San Francisco, San Francisco, CA., Krogan NJ; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA.; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, CA., Swaney DL; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA.; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, CA., Shoichet BK; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA., Ott M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.; Department of Medicine, University of California San Francisco, San Francisco, CA.; Chan Zuckerberg Biohub- San Francisco, San Francisco, CA., Renslo AR; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA., Ashworth A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Fraser JS; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Aug 29. Date of Electronic Publication: 2024 Aug 29.